Table. Efficacy of upadacitinib in moderate–severe rheumatoid arthritis.

Trial	Treatment	Efficacy - ACR20*
SELECT EARLY3 947 methotrexate-naïve patients randomised to upadacitinib or methotrexate for 12 weeks	upadacitinib 15 mg/day	76%
	upadacitinib 30 mg/day	77%
	methotrexate	54%
SELECT MONOTHERAPY4 648 patients with inadequate response to methotrexate randomised to switch to upadacitinib monotherapy or continue methotrexate for 14 weeks	upadacitinib 15 mg/day	68%
	upadacitinib 30 mg/day	71%
	methotrexate	41%
SELECT NEXT5 661 patients with inadequate response to at least one conventional DMARD (methotrexate, sulfazine or leflunomide) randomised to add upadacitinib or placebo for 12 weeks	upadacitinib 15 mg/day	64%
	upadacitinib 30 mg/day	66%
	placebo	36%
SELECT COMPARE6 1629 patients with inadequate response to methotrexate randomised to add upadacitinib, adalimumab or placebo for 48 weeks (ACR20 measured at 12 weeks)	upadacitinib 15 mg/day	71%
	adalimumab 40 mg every 2 weeks	63%
	placebo	36%
SELECT BEYOND7 499 patients with inadequate response or intolerance to biological DMARDs and receiving conventional DMARDs randomised to add upadacitinib or placebo for 12 weeks	upadacitinib 15 mg/day	65%
	upadacitinib 30 mg/day	56%
	placebo	28%

DMARD disease-modifying antirheumatic drug

* defined as the proportion of patients who had at least a 20% improvement on the American College of Rheumatology scale